Organon & Co. recently released its 10-Q report. Organon is a global healthcare company focused on women’s health and general medicines, with sales in the United States, Europe, Canada, Japan, China, Latin America, the Middle East, Africa, and other international markets. Its portfolio includes prescription therapies and medical devices across contraception, fertility, biosimilars, cholesterol management, hypertension, respiratory care, dermatology, bone health, pain management, and men’s health, and it sells through wholesalers, retailers, hospitals, government agencies, and managed-care organizations.
In Item 2, Management’s Discussion and Analysis, Organon said worldwide sales for the three months ended March 31, 2026 were $1.460 billion, down 4% from $1.513 billion a year earlier. U.S. sales fell 13% to $358 million, while international sales were flat at $1.102 billion; excluding foreign exchange, worldwide sales declined 9%. The company said foreign exchange added about $76 million, or 5%, to sales in the quarter.
The biggest sales drag came from Nexplanon, Singulair, Marvelon, Mercilon, and Ontruzant. Nexplanon sales fell because of lower physician demand in the U.S. after five-year label approval, delayed reinsertions, and uncertainty around federal funding; outside the U.S., the company cited shipment timing in emerging markets, partly offset by stronger demand and access in Brazil. Singulair declined on weaker demand tied to less favorable medical guidelines in some international markets, temporary supply constraints in Japan, and mandatory price cuts in China and Japan. Marvelon and Mercilon were hurt by weaker demand, market contraction in China, and shipment timing in Asia Pacific, while Ontruzant fell on increased international competition and lower tender volume from Brazil’s Ministry of Health.
Those declines were partly offset by higher sales of Emgality, Hadlima, Atozet, and Brenzys. Emgality benefited from continued uptake after Organon acquired distribution and promotion rights from Lilly in January 2024 in certain markets outside the U.S. Hadlima rose on stronger U.S. demand and higher demand in Puerto Rico. Atozet increased on stronger demand in China after a 2025 launch, higher volume in Asia Pacific, and uptake in parts of Europe, though pricing in Europe was unfavorable. Brenzys benefited from the timing of prior-year tenders in Brazil.
Organon said loss of exclusivity reduced sales by about $4 million in the quarter, and volume-based procurement in China cut sales by about $2 million. The company also said it expects VBP to continue weighing on its general medicines portfolio for the next several quarters.
Among recent developments, the board appointed Joseph Morrissey as interim CEO on a permanent basis on April 26, 2026. In February 2026, Organon signed an exclusive license agreement with Sebela Pharmaceuticals for global rights to Miudella, a hormone-free copper IUD approved by the FDA in February 2025; the deal calls for $27.5 million at closing, up to $505 million in sales-based milestones, and tiered double-digit royalties. In January 2026, Organon divested the Jada System to Laborie for up to $465 million, including $440 million subject to closing adjustments and up to $25 million in contingent payments tied to 2026 net sales targets. Organon said about 100 employees transferred in the transaction and it recorded an $81 million gain on the sale in other income, net. As a result of these announcements, the company's shares have moved 30.93% on the market, and are now trading at a price of $11.26. For more information, read the company's full 10-Q submission here.
